Renin inhibitors

A method of treating cardiovascular disease in a patient in need of treatment, comprising:

• administering to a patient a therapeutically effective amount of a compound having the formula
• or a pharmaceutically acceptable salt thereof, wherein:
• Y is selected from the group consisting of —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —C(R6)(R6′)—, and —C(NR6R6′)—;
• R1 is selected from the group consisting of (C1-10)alkyl, (C3-12)cycloalkyl, (C3-12)heterocycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, (C4-12)heterobicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, amino, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkenyl, alkynyl, carbonyl group, cyano, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
• R2 is selected from the group consisting of amino(C1-6)alkyl, (C3-12)heterocycloalkyl, (C4-12)heterobicycloaryl, heteroaryl, and cyano, each substituted or unsubstituted;
• R3 is selected from the group consisting of hydrogen, hydroxyl, halo, (C1-10)perhaloalkyl, amino, nitro, cyano, thio, oxy, sulfonamido, (C1-10)alkyl, (C3-12)cycloalkyl, (C3-12)heterocycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, (C4-12)heterobicycloaryl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, imino(C1-3)alkyl, (C1-10)alkylamino, amino(C1-10)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted;
• or R2 and R3 are taken together to form a ring;
• R5 and R7 are each independently selected from the group consisting of hydrogen, (C1-10)haloalkyl, amino, nitro, thio, sulfonamido, (C1-10)alkyl, (C3-12)cycloalkyl, (C3-12)heterocycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, (C9-12)bicycloaryl, (C4-12)heterobicycloaryl, (C3-12)cycloalkyl(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl group, imino group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R5 is absent when the nitrogen atom on which R5 is drawn forms part of a double bond;
• and
• R6 and R6′ are each independently selected from the group consisting of hydrogen, nitro, sulfonamido, (C1-10)alkyl, (C1-10)azaalkyl, (C1-10)oxaalkyl, (C1-10)oxoalkyl, hydroxy(C1-10alkyl, (C3-12)cycloalkyl, (C1-12)heterocycloalkyl, aryl(C1-10)alkyl, (C1-5)heteroarylalkyl, (C9-12)bicycloaryl, (C4-12)heterobicycloaryl, (C3-12)cycloalkyl(C1-10)alkyl, (C3-12)heterocycloalkyl(C1-10)alkyl, carbonyl(C1-3)alkyl, thiocarbonyl(C1-3)alkyl, sulfonyl(C1-3)alkyl, sulfinyl(C1-3)alkyl, imino(C1-3)alkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, heteroaryloxy, oxy group, carbonyl group, amino group, imino group, thio group, sulfonyl group and sulfinyl group, each substituted or unsubstituted, or R5 and R6 are taken together to form a ring, or R6′ is absent when the carbon or nitrogen atom on which R6′ is drawn forms part of a double bond, or when Y is CR6R6′, R6 and R6′ is taken together to form an oxo or a thioxo group;
• wherein the cardiovascular disease is selected from hypertension, congestive heart failure, and myocardial infarction.